Status: Not yet recruiting
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Evaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.
Participants needed: 28
Trial details
Age: 18-78Biological sex: AllType: InterventionalSponsor: Donghua ZhangUpdated: Jan 16, 2026Locations: 1
Eligibility criteria
Not listed